Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025Angela Rose, Francisco Pozo, Safraj Shahul Hameed et al.|Eurosurveillance|2025Cited by 24
COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care NetworkCharlotte Lanièce Delaunay, Nuno Verdasca, Susana Monge et al.|Influenza and Other Respiratory Viruses|2025Cited by 10
Influenza vaccine effectiveness from nine studies during drifted A(H3N2) subclade K predominance, Europe, September 2025 to January 2026Héloïse Lucaccioni, the European IVE group, Diogo F.P. Marques et al.|Eurosurveillance|2026Cited by 7
COVID-19 Vaccine Effectiveness against Medically Attended Symptomatic SARS-CoV-2 Infection among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care NetworkCharlotte Lanièce Delaunay, Esther Kissling, Nuno Verdasca et al.|SSRN Electronic Journal|2025Cited by 0
Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025Angela Rose, European IVE group, Héloïse Lucaccioni et al.|Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)|2025Cited by 0